Clinical Trial Update: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up [Phase 3]

View source ↗

Summary

Results from a Phase 3 trial evaluating the efficacy and safety of LEO 43204 for actinic keratosis on the face or chest, with 12-month follow-up.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEO 43204

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2018-12-26